OBJECTIVES: To evaluate the effect of anti- @entity310 on the @entity1198 and Th2 cytokines in @entity1 with @entity5145 ( @entity5145 ). METHODS: Peripheral blood mononuclear cells (PBMC) were obtained from 20 @entity1 with active @entity5145 treated with infliximab (5 mg/kg). For comparison, PBMC were also obtained from 15 healthy controls and 19 @entity1 with active @entity309 ( @entity309 ). After stimulation with @entity4515 / @entity1360 , the intracellular cytokines interleukin (IL)2, @entity3646 , @entity688 , and interferon ( @entity379 were determined in CD3+ T cells and in CD3+/CD56+ natural killer (NK) T cells by flow cytometry. RESULTS: At baseline the percentage of T cells positive for @entity379 (p=0.020) and @entity1199 (p=0.046) was decreased in @entity1 with @entity5145 compared with healthy controls, while @entity688 (p=0.001) was increased. This cytokine profile, confirmed by the mean fluorescence intensities (MFI), was more pronounced in CD3+/CD8- cells and contrasted with higher @entity1199 production in @entity309 . NK T cells, characterised by high @entity3646 and @entity688 numbers, were also increased in @entity1 with @entity5145 (p=0.017). Treatment with infliximab induced a significant and persistent increase in @entity379 and @entity1199 in @entity1 with @entity5145 . Moreover, there was a transient decrease in @entity688 and NK T cells in @entity1 with high baseline values, resulting in values comparable with those of healthy controls. This switch in cytokine profile was seen in both the CD3+/CD8- and CD3+/CD8+ subsets. CONCLUSIONS: Before treatment @entity1 with @entity5145 had an impaired @entity1198 cytokine profile compared with healthy controls and @entity1 with @entity309 . @entity310 blockade induced restoration of the @entity1198 cytokines, resulting in a normal cytokine balance. These data confirm the effect of anti- @entity310 on the immune changes in @entity5145 , and provide insights into the mechanisms involved in @entity310 blockade.

Impaired @entity1198 cytokine production in @entity5145 is restored by anti- XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity310 :: ('7124', 'Gene') :: ['TNFalpha'] @entity4515 :: ('CHEBI:60755', 'Chemical') :: ['PMA'] @entity1198 :: ('51497', 'Gene') :: ['Th1'] @entity1360 :: ('MESH:D015759', 'Chemical') :: ['ionomycin'] @entity379 :: ('3458', 'Gene') :: ['IFN)gamma', 'IFNgamma'] @entity5145 :: ('MESH:D025242', 'Disease') :: ['spondyloarthropathy', 'SpA'] @entity1199 :: ('3558', 'Gene') :: ['IL2'] @entity3646 :: ('3565', 'Gene') :: ['IL4'] @entity688 :: ('3586', 'Gene') :: ['IL10'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity310 :: (7124,Gene) :: ['TNFalpha']
